Interim analysis of promise, a clinical study combining the BET inhibitor OPN-2853 with ruxolitinib in patients with advanced myelofibrosis experiencing an inadequate response to ruxolitinib
Authors
Steven Knapper (ORCID: https://orcid.org/0000-0002-6405-4441)
Interim analysis of promise, a clinical study combining the BET inhibitor OPN-2853 with ruxolitinib in patients with advanced myelofibrosis experiencing an inadequate response to ruxolitinib
Steven Knapper, Jenny O’Nions, Adam J. Mead, Srinivasan Narayanan et al.
Journal
Blood
Topics
Protein Degradation and Inhibitors
article
Interim analysis of promise, a clinical study combining the BET inhibitor OPN-2853 with ruxolitinib in patients with advanced myelofibrosis experiencing an inadequate response to ruxolitinib
Steven Knapper, Jenny O’Nions, Adam J. Mead, Srinivasan Narayanan, Manish Jain, Claire Harrison, Patrick Harrington, Bethan Psaila, Frances Wadelin, Zsófia Brigitta Nagy, Mary Frances McMullin, R. G. Record, Rebecca Collings, Ayesha Begum, Rebecca H. Boucher, Kerry Inokuchi, Jackie Walling, Jiayi Wang, Sebastian Francis, B HUNTLEY
article en
Abstract
No abstract available for this paper.
Publication Tag
BloodVol. 146(Supplement 1)
Institutions
Birmingham City University (GB), Belfast Health and Social Care Trust (GB), University College Hospital (GB), Cardiff and Vale University Health Board (GB), Nottingham University Hospitals NHS Trust (GB), University College London Hospitals NHS Foundation Trust (GB), Guy's and St Thomas' NHS Foundation Trust (GB), Leeds Teaching Hospitals NHS Trust (GB), John Radcliffe Hospital (GB), University Hospital Southampton NHS Foundation Trust (GB), University of Oxford (GB), Sheffield Teaching Hospitals NHS Foundation Trust (GB), Mission Bio (United States) (US), Cancer Research UK Clinical Trials Unit (GB), Stem Cell Institute (PA), University College London (GB), University of Birmingham (GB)